

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Diltiazem Hydrochloride for Injection (10mg) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation. Diltiazem Hydrochloride for Injection is mainly used in supraventricular tachycardia, emergency treatment of abnormally high blood pressure during surgery, hypertensive emergencies, and unstable angina.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg) from the NMPA, being under type 3 and regarded as passing the consistency evaluation. Propranolol Hydrochloride Injection is mainly used in control of supraventricular tachyarrhythmias and ventricular arrhythmias, exertional angina, and Pheochromocytoma (used together with  $\alpha$ -blockers to control tachycardia). As stated in the Company’s announcement dated 13 February 2026, the Group’s Propranolol Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

**Chow Hing Yeung**

*Executive Director and Company Secretary*

Hong Kong, 27 April 2026

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*